Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: The importance of PSA nadir before radiation

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 5, 2005, Pages 1309-1315

  Ludgate, Charles M ^a   Bishop, Darcy C ^a   Pai, Howard ^a   Eldridge, Brenna ^a   Lim, Jan ^a   Berthelet, Eric ^a   Blood, Paul ^a   Piercy, G Bruce ^b   Steinhoff, Gary ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

Author keywords

Hormone therapy; Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

DISEASES; HORMONES; PATIENT TREATMENT; RADIATION; RADIOTHERAPY;

EXTERNAL BEAM RADIATION THERAPY (EBRT); HIGH RISK PROSTATE ADENOCARCINOMA; MULTI VARIATE ANALYSIS; NEOADJUVANT HORMONE THERAPY;

TUMORS;

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BEAM THERAPY; BIOCHEMISTRY; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REVIEW;

EID: 22144463788     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.01.001     Document Type: Article

References (22)

1. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial Lancet 360 2002 103 106
2. C.A. Lawton, K. Winter, K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
3. M.V. Pilepich, K. Winter, M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
4. J. Laverdiere, A. Nabid, L.D. De Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140
5. A.L. Zietman, E.A. Prince, B.M. Nakfoor Androgen deprivation and radiation therapy Sequencing studies using the Shionogi in vivo tumor system Int J Radiat Oncol Biol Phys 38 1997 1067 1070
6. J.M. Kaminski, A.L. Hanlon, D.L. Joon Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth Int J Radiat Oncol Biol Phys 57 2003 24 28
7. J. Crook, C. Ludgate, S. Malone Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23
8. M.J. Zelefsky, O. Lyass, Z. Fuks Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy J Clin Oncol 16 1998 3380 3385
9. M. Sumi, H. Ikeda, K. Tokuuye The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma Int J Radiat Oncol Biol Phys 48 2000 519 528
10. C.M. Ludgate, J.T. Lim, A.G. Wilson Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer Vancouver Island Cancer Centre experience Can J Urol 7 2000 937 943
11. H. Lukka, P. Warde, T. Pickles Controversies in prostate cancer radiotherapy Consensus development Can J Urol 8 2001 1314 1322
12. H.B. Kal, M.P. Van Gellekom How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 57 2003 1116 1121
13. T. Pickles, C. Kim-Sing, W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18
14. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
15. M.E. Gleave, S.L. Goldenberg, J.L. Chin Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy Biochemical and pathological effects J Urol 166 2001 500 506
16. D.L. Joon, M. Hasegawa, C. Sikes Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation Int J Radiat Oncol Biol Phys 38 1997 1071 1077
17. A. Pollack, N. Salem, F. Ashoori Lack of prostate cancer radiosensitization by androgen deprivation Int J Radiat Oncol Biol Phys 51 2001 1002 1007
18. N. Green, H. Bodner, E. Broth Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy Int J Radiat Oncol Biol Phys 10 1984 971 976
19. M.E. Gleave, S.L. Goldenberg, E.C. Jones Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1996 213 219
20. G.E. Hanks, T.F. Pajak, A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
21. A.V. D'Amico, J. Manola, M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer A randomized controlled trial JAMA 292 2004 821 827
22. J.M. Holzbeierlein, E. Castle, J.B. Thrasher Complications of androgen deprivation therapy Prevention and treatment Oncology 18 2004 303 309